Arginine Vasopressin: An Immunoregulatory Hormone

Quintanar‐Stephano, Andrés; Organista-Esparza, Alejandro; Chavira-Ramírez, Roberto; Campos-Rodrı́guez, Rafael; Berczi, István; Kovács, Kálmán

doi:10.1016/b978-0-12-801770-8.00005-7

Cited by 3 publications

(5 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yan-Hong et al [ 29 ] described the effect of AVP on cardiac fibroblast differentiation into collagen producer myofibroblasts, and Niu et al [ 28 ] found a synergistic effect of angiotensin (fragments 1-7) and AVP on proliferation and collagen synthesis in rat cardiac fibroblasts. The presence of V1a and V2 AVP receptors in immune system cells and its stimulatory role during inflammatory responses has also been demonstrated [ 40 ]. AVP V1a receptors were present in blood monocytes, macrophages, splenic lymphocytes, and B cells; V2 AVP receptors in peripheral blood cell cultures; and V1b receptors in the thymus and spleen cells.…”

Section: Discussionmentioning

confidence: 99%

Recovery from Liver Failure and Fibrosis in a Rat Portacaval Anastomosis Model after Neurointermediate Pituitary Lobectomy

Muñoz‐Ortega

Macías-Segura

Ventura‐Juárez

et al. 2021

Journal of Immunology Research

Self Cite

View full text Add to dashboard Cite

Liver diseases, including cirrhosis, viral hepatitis, and hepatocellular carcinoma, account for approximately two million annual deaths worldwide. They place a huge burden on the global healthcare systems, compelling researchers to find effective treatment for liver fibrosis-cirrhosis. Portacaval anastomosis (PCA) is a model of liver damage and fibrosis. Arginine vasopressin (AVP) has been implicated as a proinflammatory-profibrotic hormone. In rats, neurointermediate pituitary lobectomy (NIL) induces a permanent drop (80%) in AVP serum levels. We hypothesized that AVP deficiency (NIL-induced) may decrease liver damage and fibrosis in a rat PCA model. Male Wistar rats were divided into intact control (IC), NIL, PCA, and PCA+NIL groups. Liver function tests, liver gene relative expressions (IL-1, IL-10, TGF-β, COLL-I, MMP-9, and MMP-13), and histopathological assessments were performed. In comparison with those in the IC and PCA groups, bilirubin, protein serum, and liver glycogen levels were restored in the PCA+NIL group. NIL in the PCA animals also decreased the gene expression levels of IL-1 and COLL-I, while increasing those of IL-10, TGF-β, and MMP-13. Histopathology of this group also showed significantly decreased signs of liver damage with lower extent of collagen deposition and fibrosis. Low AVP serum levels were not enough to fully activate the AVP receptors resulting in the decreased activation of cell signaling pathways associated with proinflammatory-profibrotic responses, while activating cell molecular signaling pathways associated with an anti-inflammatory-fibrotic state. Thus, partial reversion of liver damage and fibrosis was observed. The study supports the crucial role of AVP in the inflammatory-fibrotic processes and maintenance of immune competence. The success of the AVP deficiency strategy suggests that blocking AVP receptors may be therapeutically useful to treat inflammatory-fibrotic liver diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

Recovery from Liver Failure and Fibrosis in a Rat Portacaval Anastomosis Model after Neurointermediate Pituitary Lobectomy

Muñoz‐Ortega

Macías-Segura

Ventura‐Juárez

et al. 2021

Journal of Immunology Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…In 1983, Locher et al (1983) described in in vitro assays the increase in prostaglandin E2 (PGE2) levels in human mononuclear phagocytes in response to AVP and desmopressin (dDAVP) suggested the presence of V2 AVP receptors ( Quintanar-Stephano et al, 2012 ). The effect of PGE2 on cAMP metabolism increased 5- to 7-fold in the presence of AVP, and the presence of AVP receptors in PBMCs is associated with increased lymphocyte proliferation in the presence of increased AVP concentrations, demonstrating the immunoregulatory role of AVP ( Locher et al, 1983 ; Quintanar-Stephano et al, 2016 ). On the other hand, AVP deficiency can induce disorders associated with immune response; for instance, the Brattleboro rat strain developed diabetes insipidus (DI) because of mutations in genes that regulate the production of AVP.…”

Section: Introductionmentioning

confidence: 97%

“…Immune studies in these animals showed that innate, humoral, and cell mediated immune responses were decreased (not suppressed) ( Quintanar-Stephano et al, 2012 ; Quintanar-Stephano et al, 2019 ). Experiments in NIL Lewis rats immunized for EAE, showed that NIL animals developed just a mild clinical symptom of EAE, whereas desmopressin administration (an agonist of V2 AVP receptors) restored the susceptibility of these animals to EAE ( Quintanar-Stephano et al, 2016 , 2012 , 2018 ). Similarly, AVP is involved in some CNS disorders, such as stroke, brain edema, ischemia, and modulation of the IS in EAE ( Hedna et al, 2014 ; Zeynalov et al, 2015 ; Viñuela-Berni et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

“…On the other hand, AVP deficiency can induce disorders associated with immune response; for instance, the Brattleboro rat strain developed diabetes insipidus (DI) because of mutations in genes that regulate the production of AVP. These animals showed a significant decrease in the number of blood lymphocytes, macrophage activity, and dysregulation of principal lymphoid organs [revised in Quintanar-Stephano et al (2016) ].…”

Section: Introductionmentioning

confidence: 99%

“…AVP is a pleotropic hormone that participates in water regulation, vasoconstriction, bone formation, glycogenolysis, platelet aggregation, antilipolytic effects, and impaired social behavior; however, the effects of AVP on the IS remains unclear. Evidence indicates that AVP plays a key immunostimulating role as an immune regulator in in vitro (autologous lymphocytes and splenocytes) and in vivo models ( Quintanar-Stephano et al, 2016 ).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Arginine vasopressin hormone receptor antagonists in experimental autoimmune encephalomyelitis rodent models: A new approach for human multiple sclerosis treatment

et al. 2023

Self Cite

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a chronic demyelinating and neurodegenerative disease that affects the central nervous system. MS is a heterogeneous disorder of multiple factors that are mainly associated with the immune system including the breakdown of the blood-brain and spinal cord barriers induced by T cells, B cells, antigen presenting cells, and immune components such as chemokines and pro-inflammatory cytokines. The incidence of MS has been increasing worldwide recently, and most therapies related to its treatment are associated with the development of several secondary effects, such as headaches, hepatotoxicity, leukopenia, and some types of cancer; therefore, the search for an effective treatment is ongoing. The use of animal models of MS continues to be an important option for extrapolating new treatments. Experimental autoimmune encephalomyelitis (EAE) replicates the several pathophysiological features of MS development and clinical signs, to obtain a potential treatment for MS in humans and improve the disease prognosis. Currently, the exploration of neuro-immune-endocrine interactions represents a highlight of interest in the treatment of immune disorders. The arginine vasopressin hormone (AVP) is involved in the increase in blood−brain barrier permeability, inducing the development and aggressiveness of the disease in the EAE model, whereas its deficiency improves the clinical signs of the disease. Therefore, this present review discussed on the use of conivaptan a blocker of AVP receptors type 1a and type 2 (V1a and V2 AVP) in the modulation of immune response without completely depleting its activity, minimizing the adverse effects associated with the conventional therapies becoming a potential therapeutic target in the treatment of patients with multiple sclerosis.

show abstract

Arginine vasopressin (AVP) treatment increases the expression of inhibitory immune checkpoint molecules in monocyte-derived dendritic cells

Ghahramanipour,

Naseri,

Mardi

et al. 2024

Immunol Res

View full text Add to dashboard Cite

Arginine Vasopressin: An Immunoregulatory Hormone

Cited by 3 publications

References 80 publications

Recovery from Liver Failure and Fibrosis in a Rat Portacaval Anastomosis Model after Neurointermediate Pituitary Lobectomy

Recovery from Liver Failure and Fibrosis in a Rat Portacaval Anastomosis Model after Neurointermediate Pituitary Lobectomy

Arginine vasopressin hormone receptor antagonists in experimental autoimmune encephalomyelitis rodent models: A new approach for human multiple sclerosis treatment

Arginine vasopressin (AVP) treatment increases the expression of inhibitory immune checkpoint molecules in monocyte-derived dendritic cells

Contact Info

Product

Resources

About